The biological activity of auranofin: implications for novel treatment of diseases (Q38042341)

27 August 2017

title

The biological activity of auranofin: implications for novel treatment of diseases (English)

1 reference

27 August 2017

J M Madeira

1

1 reference

27 August 2017

D L Gibson

series ordinal

2

1 reference

27 August 2017

W F Kean

series ordinal

3

1 reference

27 August 2017

A Klegeris

series ordinal

4

1 reference

27 August 2017

publication date

11 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

20

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

297-306

1 reference

Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Immunologic therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Auranofin protects against cocaine-induced hepatic injury through induction of heme oxygenase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Inflammation and cancer: back to Virchow?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Gold compounds as therapeutic agents for human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a single thioredoxin glutathione reductase and dependent on selenium and glutathione.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Investigation of a potential mechanism for the inhibition of SmTGR by Auranofin and its implications for Plasmodium falciparum inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

The influence of auranofin, a clinically established antiarthritic gold drug, on bone metabolism: analysis of its effects on human multipotent adipose-derived stem cells, taken as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Host factors and the pathogenesis of HIV-induced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

HIV therapeutic possibilities of gold compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Thioredoxin reductase activity is decreased by selenium deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Inhibition of selenium metabolism in the oral pathogen Treponema denticola

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Intramuscular versus oral gold therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Clinical pharmacology of gold

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

The history of gold therapy in rheumatoid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Auranofin, a gold(I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

In vitro killing action of auranofin on Taenia crassiceps metacestode (cysticerci) and inactivation of thioredoxin-glutathione reductase (TGR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Auranofin protects against anthrax lethal toxin-induced activation of the Nlrp1b inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Gold-induced reactive oxygen species (ROS) do not mediate suppression of monocytic mitochondrial or secretory function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Heme oxygenase-1: unleashing the protective properties of heme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

21 January 2018

Systemic gold therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Heat shock-induced matrix metalloproteinase (MMP)-1 and MMP-3 are mediated through ERK and JNK activation and via an autocrine interleukin-6 loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

TBK1-targeted suppression of TRIF-dependent signaling pathway of toll-like receptor 3 by auranofin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

A report from the XVIII International AIDS Conference. (July 18-23, 2010-Vienna, Austria).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Thioredoxin reductase-2 is essential for keeping low levels of H(2)O(2) emission from isolated heart mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Anti-rheumatic gold compounds as sublethal modulators of monocytic LPS-induced cytokine secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Free radicals, metals and antioxidants in oxidative stress-induced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Biologic actions and pharmacokinetic studies of auranofin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Auranofin inhibits interleukin-1beta-induced transcript of cyclooxygenase-2 on cultured human synoviocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Targeted gene deletion of heme oxygenase 2 reveals neural role for carbon monoxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

Malaria research in the post-genomic era

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-012-0149-1

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

12 December 2020

Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages

1 reference

12 December 2020

Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

1 reference

12 December 2020

Life in the 21st century - a vision for all

1 reference

12 December 2020

Inhibition of neovascularization in vivo by gold compounds

1 reference

12 December 2020

1 reference

12 December 2020

Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3

1 reference

12 December 2020

Treatment of HIV associated psoriatic arthritis with oral gold

1 reference

12 December 2020

Quantitative relationship of Treponema denticola to severity of periodontal disease

1 reference

12 December 2020

Intestinal uptake and metabolism of auranofin, a new oral gold-based antiarthritis drug

1 reference

12 December 2020

10.1007/S10787-012-0149-1

Identifiers

DOI

1 reference

27 August 2017

1 reference